Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Harriette Van Spall , Added: 1 year ago
AHA Conference 2024 — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD).The FLOW trial (NCT03819153) is designed to assess the effect of… View more
Author(s): Steven E Nissen Added: 1 year ago
Is BMI the best indicator to identify CVD patients who can be treated with GLP-1 RAs and other weight management therapies?In this short interview, Dr Steven Nissen (Cleveland Clinic, Cleveland, US) discusses how to determine which CVD patients will benefit most from treatment with GLP-1 RAs. He highlights how lifestyle changes are often ineffective in achieving weight loss goals, and therefore,… View more
Author(s): Danxia Yu Added: 1 year ago
Outcomes from a new CV disease risk assessment tool show significant improvements in CV, kidney and metabolic health after bariatric surgery. The study also found a reduction in estimated 10 year risk of developing total CV disease and a reduction in the risk of developing heart failure one year after bariatric surgery.In this short interview, Dr Danxia Yu (Vanderbilt University Medical Center,… View more
Author(s): Faiez Zannad Added: 1 year ago
Although cardio-kidney-metabolic disease (CKMD) incorporates conditions which share common risk factors, guidelines are often complex and vary between specialist groups. How can we achieve simpler CKMD guidelines to improve implementation?In this short interview, Dr Faiez Zannad (University of Lorraine, Nancy, FR) advocates for a single-set of overarching CKMD guidelines across all specialties… View more
Author(s): Nils Krüger Added: 5 months ago
AHA Scientific Sessions 2025 - Dr Nils Krüger (Brigham and Women's Hospital, US) joins us to discuss findings from the TIRZSEMA-CVOT (NCT07096063) study, examining real-world cardiovascular outcomes with tirzepatide and semaglutide in patients with type 2 diabetes at cardiovascular risk.This retrospective cohort study utilized three national US claims databases to evaluate over 887,000 patients… View more